Minoxidil is a potent vasodilator primarily used for the treatment of severe hypertension,and androgenic alopecia.Although known adverse effects include fluid retention,tachycardia and hypertrichosis,its potential to ...Minoxidil is a potent vasodilator primarily used for the treatment of severe hypertension,and androgenic alopecia.Although known adverse effects include fluid retention,tachycardia and hypertrichosis,its potential to induce coronary vasospasm remains largely underreported.[1]Minoxidil is currently reserved for treating alopecia for various causes.展开更多
Objective:To analyze the efficacy of Tongxinluo Capsules in treating coronary heart disease(CHD)with angina pectoris.Methods:A total of 98 patients with CHD and angina pectoris admitted between May 2022 and May 2025 w...Objective:To analyze the efficacy of Tongxinluo Capsules in treating coronary heart disease(CHD)with angina pectoris.Methods:A total of 98 patients with CHD and angina pectoris admitted between May 2022 and May 2025 were enrolled and randomly divided into a control group and an experimental group,with 49 cases each.The control group was treated with atorvastatin+clopidogrel,while the experimental group received atorvastatin+clopidogrel+Tongxinluo Capsules.Clinical efficacy,cardiac function,angina attack frequency and duration,and adverse reactions were compared between the two groups.Results:The experimental group showed higher clinical efficacy than the control group(P<0.05).Cardiac function in the experimental group was superior to that of the control group(P<0.05).The duration and frequency of angina attacks in the experimental group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The use of Tongxinluo Capsules in the clinical treatment of CHD with angina pectoris can improve various clinical indicators,enhance therapeutic efficacy,and promote faster patient recovery.展开更多
Objective:To analyze the therapeutic efficacy of Shexiang Baoxin Pill combined with Rosuvastatin Calcium Tablets(ROS)in patients with angina pectoris due to coronary atherosclerotic heart disease(CHD-AP).Methods:Eight...Objective:To analyze the therapeutic efficacy of Shexiang Baoxin Pill combined with Rosuvastatin Calcium Tablets(ROS)in patients with angina pectoris due to coronary atherosclerotic heart disease(CHD-AP).Methods:Eighty CHD-AP patients admitted for treatment from January 2023 to December 2024 were selected and evenly divided using a random number table.The combined group(40 cases)received treatment with Shexiang Baoxin Pill combined with ROS,while the reference group(40 cases)received ROS monotherapy.The overall response rate,frequency and duration of AP attacks,blood lipid levels,and cardiac function indicators were compared between the two groups.Results:The combined group exhibited a higher overall response rate than the reference group.After treatment,the frequency and duration of AP attacks were lower in the combined group than in the reference group.Additionally,blood lipid levels and cardiac function indicators were superior in the combined group(p<0.05).Conclusion:The combination of Shexiang Baoxin Pill and ROS demonstrates favorable therapeutic effects in CHD-AP patients,effectively preventing AP attacks,regulating blood lipid levels,protecting cardiac function,and reducing disease risk.展开更多
Objective:To investigate the clinical efficacy of Shexiang Tongxin Dropping Pills combined with rosuvastatin calcium and clopidogrel bisulfate tablets in treating phlegm-heat and blood stasis type angina pectoris of c...Objective:To investigate the clinical efficacy of Shexiang Tongxin Dropping Pills combined with rosuvastatin calcium and clopidogrel bisulfate tablets in treating phlegm-heat and blood stasis type angina pectoris of coronary heart disease.Methods:Sixty-four patients with phlegm-heat and blood stasis type angina pectoris of coronary heart disease,hospitalized at Lin’an District Hospital of Traditional Chinese Medicine from January 2024 to April 2025,were selected and randomly divided into a control group(administered 10mg of rosuvastatin calcium and 75mg of clopidogrel bisulfate once daily)and an observation group(administered 2 Shexiang Tongxin Dropping Pills three times daily in addition to the control group’s treatment regimen),with 32 patients in each group.The therapeutic effects of the two groups were compared.Results:After 56 days of treatment,the angina pectoris score in the observation group was significantly lower than that in the control group(4.49±0.39 vs 4.88±0.47,p<0.05);the Seattle Angina Questionnaire(SAQ)score indicated improvement in the frequency of angina pectoris attacks.(SAQ-AF:71.35±5.29 vs.64.25±7.55,p<0.05)and treatment satisfaction(SAQ-TS:58.79±6.22 vs.54.16±5.02,p<0.05)were more significantly improved in the observation group.The total effective rate(96.87%vs.90.62%,p<0.05)and marked effective rate(62.50%vs.31.25%)were higher in the observation group than in the control group.The Traditional Chinese Medicine(TCM)syndrome score(4.49±0.39 vs.4.88±0.47,p<0.05)and lipid index(LDL-C:1.79±0.31 vs.1.99±0.33 mmol/L,p<0.05)decreased more significantly in the observation group.Conclusion:Shexiang Tongxin Dropping Pills combined with rosuvastatin calcium and clopidogrel bisulfate tablets demonstrated good efficacy and high safety in the treatment of phlegm-heat and blood stasis type angina pectoris associated with coronary heart disease.展开更多
OBJECTIVE: To ascertain whether continuous treatment with Traditional Chinese Medicine(TCM) combined with standardized drug therapy from Western Medicine can further reduce the incidence of cardiovascular events in pa...OBJECTIVE: To ascertain whether continuous treatment with Traditional Chinese Medicine(TCM) combined with standardized drug therapy from Western Medicine can further reduce the incidence of cardiovascular events in patients with coronary heart disease and angina and reduce the incidence of angina pectoris in patients with coronary heart disease.METHODS: A multicenter, prospective cohort study of 1042 patients in 22 hospitals was conducted. A total of 423 patients with angina pectoris were treated with standardized Western Medicine alone(control group) and 619 with a combination of Chinese and Western Medicine(exposure group). The two groups underwent follow-up for 1 year to establish whether there was any improvement in the incidence of cardiovascular events or change in the curative effect.RESULTS: The incidence of primary endpoint events in the combined-exposure group decreased by 0.45%(P > 0.05) and the incidence of secondary terminal events decreased by 5.25% in comparison with the control group(P < 0.05). The total angina pectoris score clearly decreased in the Western Medicine group over the first 6 months, but the decline was more apparent in the combined-exposure group.CONCLUSION: Compared with treatment using standardized Western Medicine alone, providing TCM combined with Western medical treatment reduced the incidence of cardiovascular events in patients with stable angina pectoris(grade Ⅱ endpoint) and effectively improved the curative effect.展开更多
OBJECTIVE:To assess the clinical efficacy and safety of ginkgo injections(GIs)combined with conventional treatment(CT)against angina pectoris(AP)due to coronary heart disease(CH D).METHODS:Randomized controlled trials...OBJECTIVE:To assess the clinical efficacy and safety of ginkgo injections(GIs)combined with conventional treatment(CT)against angina pectoris(AP)due to coronary heart disease(CH D).METHODS:Randomized controlled trials(RCTs)that used GIs to treat AP were searched in SinoMed,PubMed,China National Knowledge Infrastructure Database,Chinese Scientific Journals Database,Wanfang Database,Embase and Cochrane Library until March 2017.The Cochrane "risk of bias" method was used to evaluate the methodological quality of RCTs.Data were analyzed using Stata v13.1 and WinBUGS v1.4.3.RESULTS:A total of 73 RCTs involving 7621 patients were included.A Bayesian network Meta-analysis of RCTs was undertaken,and the advantages of four types of Gl-supplemented CT in AP treatment were determined.CONCLUSION:Gl-assisted CT was more effective against AP than CT alone.However,based on the limitations of the study,additional high-quality RCTs are required to confirm our findings.展开更多
OBJECTIVE:To evaluate the clinical efficacy of Traditional Chinese Medicine prescriptions for resolving phlegm in the treatment of angina pectoris of phlegmstasis coronary heart disease by a network Meta-analysis.METH...OBJECTIVE:To evaluate the clinical efficacy of Traditional Chinese Medicine prescriptions for resolving phlegm in the treatment of angina pectoris of phlegmstasis coronary heart disease by a network Meta-analysis.METHODS:Randomized controlled trials(RCTs)on clinical efficacy of CHD angina pectoris with interaction of phlegm and blood stasis were searched in PubMed,Springer,the Cochrane Library and Chinese-language databases China National Knowledge Infrastructure,China Science and Technology Journal Database,and Wanfang Data from their inception to December 2021.Literature was screened and literature bias risk was assessed by RevMan5.4 software.The overall response rate,the duration of angina attack,the levels of serum lipids such as total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C),and high density lipoprotein cholesterol(HDL-C),and expression of hypersensitive C-reactive protein(hs-CRP)were selected as outcome indicators for network Meta-analysis and mapped using Stata15.1 software.RESULTS:Totally,26 RCTs were included,involving 2098 participants.There were 6 TCM formulas with the effects of dispelling phlegm and removing blood stasis.Taking conventional Western Medicine as the common intervention measures,the results showed that the overall response improvement rate from high to low was displayed as modified Xiaoxianxiong decoction(小陷胸汤,MXD),Danlou tablet(丹蒌片,DT),modified Gualou Xiebai Banxia decoction(瓜蒌薤白半夏汤,MGXBD),modified Wendan decoction(温胆汤,MWD),modified Zhishi Xiebai Guizhi decoction(枳实薤白桂枝汤,MZXGD),and modified Erchen decoction(二陈汤,MED).The sequence of angina attack duration improvement from high to low was MZXGD,MGXBD,DT,MWD,MXD.The sequence of TC improvement from high to low was MZXGD,MED,DT,and MGXBD.Sequence of improving TG from high to low was MED,MZXGD,MGXBD,and DT.For LDL-C improvement,the effect from good to poor was MZXGD,MGXBD,DT,and MED.With regard to HDL-C improvement,the effect was ranked as MED,MZXGD,MGXBD,and DT from good to poor.hs-CRP expression from high to low was MZXGD,MXD,MED,MWD,and MGXBD.CONCLUSION:TCM formula with the effects of dispelling phlegm and removing blood stasis combined with conventional Western Medicine has obvious advantages in treating CHD angina pectoris with interaction of phlegm and blood stasis.MZXGD has great potential in increasing the overall response rate,reducing Duration of angina attack improving blood lipids,and reducing inflammatory factors.However,due to the limitations of extant studies,the conclusions of this study need to be confirmed by numerous reasonably-designed RCTs.展开更多
OBJECTIVE： To study the preventative effects of Dongchongxiacao （Cordyceps） on contrast-induced nephropathy （CIN） in patients with stable angina pectoris （SAP）. METHODS： One-hundred and three SAP inpatients we...OBJECTIVE： To study the preventative effects of Dongchongxiacao （Cordyceps） on contrast-induced nephropathy （CIN） in patients with stable angina pectoris （SAP）. METHODS： One-hundred and three SAP inpatients were divided randomly into two groups： basic treat- ment （n=51） and Dongchongxiacao （Cordyceps） treatment （n=52）; corbrin capsules （3 g; t.d.s.） were used 3 days before angioplasty and 3 days after an- gioplasty）. Serum creatinine （Scr） was assessed at the time of hospital admission and 1, 2, and 3 days after angioplasty. Values of kidney injury mole- cule-1 （KIM-1）, neutrophil gelatinase-associated li- pocalin （NGAL） and interleukin （IL） 18 in the kidney were detected before angioplasty and 1 day after angioplasty in the patients of both groups. The prevalence of CIN between the two groups was then compared. RESULTS： CIN occurred in 9 of 103 patients （8.74%）. The prevalence of CIN in the Dongchongxiacao （Cordyceps） treatment group was lower than that of the basic treatment group （5.77% vs 11.76%） but the difference was not significant （P〉0.05）. The post-procedure mean peak of Scr, post-procedure increase in Scr levels from baseline, and urine levelsof KIM-1, NGAL and IL18 after the procedure in the Dongchongxiacao （Corclyceps） treatment group were significantly lower than those in the basic treatment group （P〈0.05）. CONCLUSION： Prophylactic treatment with Dongchongxiacao （Cordyceps） in SAP patients who undergo coronary angiography or coronary inter- vention could prevent contrast-induced renal im- pairment.展开更多
Objective： To investigate the relationship between serum resistin level and acute coronary syndrome （ACS） or stable angina pectoris （SAP）. Methods： Sixty-five patients, with coronary artery disease, were enrolle...Objective： To investigate the relationship between serum resistin level and acute coronary syndrome （ACS） or stable angina pectoris （SAP）. Methods： Sixty-five patients, with coronary artery disease, were enrolled and divided into three subgroups： acute myocardial infarction （AMI）, unstable angina pectoris （UAP） and SAP, and 26 healthy people were recruited as controls in the cross-sectional study. Serum resistin levels were determined by ELISA （enzyme-linked immunosorbent assay）, and WBC （white blood cell count）, hsCRP （high sensitive C-reaction protein）, CKmax （maximum of creatinkinase）, CK-MBmax （maximum of isozyme of creatinkinase） and cTnImax （maximum of troponin） were measured by standard laboratory methods. Results： The serum resistin levels were 4 folds higher in AMI patients, 2.43 folds in UAP patients and I. 12 folds in SAP patients than in the healthy controls （P〈0.05）. The resistin levels were also significantly different between AMI [（8.16±0.79） ng/ml], UAP [（5.59±0.75） ng/ml] and SAP [（3.45±0.56） ng/ml] groups （P〈0.01）; WBC, hsCRP, CK CK-MBmax and cTnlmax were significantly increased in AMI patients over UAP and SAP patients. Spearman analysis showed that serum resistin levels were positively correlated with WBC （r=0.412, P=0.046）, hsCRP （r=0.427,p=0.037）, CK CK-MBmax and cTnImax （r=0.731, 0.678, 0.656; P〈0.01）. Conclusion： Serum resistin levels increased with inflammatory factors and myocardial impairment. The results suggest that human resistin might play an important role in the pathogenesis of atherosclerosis and AMI as an inflammatory factor.展开更多
Objective： To evaluate the clinical effect and safety of Safflower Yellow injection （SYI） in treating coronary heart disease angina pectoris （OHD-AP） with Xin-blood stagnation syndrome （XBSS）. Methods： Adopted...Objective： To evaluate the clinical effect and safety of Safflower Yellow injection （SYI） in treating coronary heart disease angina pectoris （OHD-AP） with Xin-blood stagnation syndrome （XBSS）. Methods： Adopted was the multi-centered, randomized, positive parallel controlled method, 448 patients with CHD-AP-XBSS were enrolled and divided into two groups, 336 in the tested group treated with SYI and 112 in the control group treated with Salvia injection by intravenous dripping once a day for 14 days, so as to observe the conditions of angina, electrocardiogram, and therapeutic effect on traditinal Chinese medicine （TCM） symptoms as well as the safety of the treatment. Results： The significantly effective rate and total effective rate in the tested group were 60.06% （194/323） and 91.02 % （294/323） respectively; those in improvement of TOM symptoms were 40. 18% （129/321） and 75.23% （243/323） respectively, which were better than those in the control group （P〈0.01）. Conclusion： SYI Injection is effective and safe in treating OHD-AP-XBSS.展开更多
OBJECTIVE: To systematically assess the effects and safety of Sini decoction as an adjuvant therapy for patients with angina pectoris.METHODS: We searched Pub Med, Excerpt Medica Database, the Cochrane library, Wanfan...OBJECTIVE: To systematically assess the effects and safety of Sini decoction as an adjuvant therapy for patients with angina pectoris.METHODS: We searched Pub Med, Excerpt Medica Database, the Cochrane library, Wanfang Database,China National Knowledge Infrastructure Database,China Science and Technology Journal Database from the date of its inception until August 1, in2014. Available literatures were selected according to the inclusion criteria. Two reviewers finished data extraction, checked the data and assessed the methodological quality of studies, independently.The Review Manage Software 5.1.0 was used for data analysis.RESULTS: Six trials involving 453 participants were eligible. None of the trials reported the mortality due to angina pectoris. The secondary outcomes showed that Sini decoction, together with nitroglycerin when necessary, may have some effects on reducing the number of angina attacks and the amount of nitroglycerin. But in terms of reducing the duration of angina and improvement of electrocardiogram, there were no statistical differences between Sini decoction group and isosorbide dinitrate group. Only one reported that no adverse events were found.CONCLUSION: Based on this systematic review, Sini decoction can reduce the dosage of nitroglycerin, when compared with isosorbide dinitrate group.And there were no enough evidence in the papers to draw any conclusions for the safety of Sini decoction.展开更多
Background The left atrial size has been considered as a useful marker of adverse cardiovascular outcomes. However, it is not well known whether left atrial area index （LAAI） has predictive value for prognosis in pa...Background The left atrial size has been considered as a useful marker of adverse cardiovascular outcomes. However, it is not well known whether left atrial area index （LAAI） has predictive value for prognosis in patients with unstable angina pectoris （UAP）. This study was aimed to assess the association between LAAI and outcomes in UAP patients. Methods We enrolled a total of 391 in-hospital patients diag- nosed as UAP. Clinical and echocardiographic data at baseline were collected. The patients were followed for the development of ad- verse cardiovascular （CV） events, including hospital readmission for angina pectoris, acute myocardial infarction （AMI）, congestive heart failure （CHF）, stroke and all-cause mortality. Results During a mean follow-up time of 26.3±8.6 months, 98 adverse CV events occurred （84 hospital readmission for angina pectoris, four AMI, four CHF, one stroke and five all-cause mortality）. In a multivariate Cox model, LAAI [OR： 1.140, 95% CI： 1.01±1.279, P = 0.026], diastolic blood pressure （OR： 0.976, 95% CI： 0.956-0.996, P = 0.020） and pulse pressure （OR 1.020, 95% CI： 1.007-1.034, P = 0.004） were independent predictors for adverse CV events in UAP patients. Conclusions LAAI is a predictor of adverse CV events independent of clinical and other echocardiographic parameters in UAP patients.展开更多
OBJECTIVE: To use a Meta-analysis to review the efficacy and safety of Gualoupi(Pericarpium Trichosanthis) injection(PTI) in the treatment of angina pectoris.METHODS: We searched the available literature up to January...OBJECTIVE: To use a Meta-analysis to review the efficacy and safety of Gualoupi(Pericarpium Trichosanthis) injection(PTI) in the treatment of angina pectoris.METHODS: We searched the available literature up to January 2015 using Chinese National Knowledge Infrastructure(CNKI), Chinese Scientific Journal Database(VIP), the Wanfang database, Pub Med and other English language databases to identify randomized controlled trials of PTI for the treatment of angina pectoris. Two reviewers independently retrieved and extracted the information. Software Review Manager 5.3 was used for statistics analysis.RESULTS: Fourteen studies involving 1621 patients were identified. Compared with conventional therapy alone or conventional therapy plus other Traditional Chinese Injections(TCMIs), PTI plus conventional therapy significantly improved clinical efficacy [odds ratio(OR) = 3.56, 95% confidence interval(CI)(2.65, 4.77)](based on 14 studies), electrocardiograph efficacy [OR = 3.20, 95% CI(2.26, 4.51)](based on 7 studies), and efficacy for Traditional Chinese Medicine Syndromes [OR = 3.13, 95% CI(1.43, 6.89)](based on 3 studies). Moreover, compared with conventional therapy alone or conventional therapy plus other TCMIs, PTI plus conventional therapy significantly decreased the levels of plasma viscosity [mean difference(MD) =- 0.47,95% CI(-0.76,-0.17)](based on 3 studies), and plasma low-density lipoprotein [MD =-0.94, 95%CI(-1.57,-0.30)](based on 3 studies). Eleven studies reported some mild adverse reactions, and no seriousadversedrugreactionswereobserved.CONCLUSION: PTI was found to be effective and safe for the treatment of angina pectoris. This study had certain limitations; thus, more rigorously designed, multi-center, randomized controlled trials in larger populations should be performed to support this observation.展开更多
Objective. To determine whether serum vascular endothelial growth factor(VEGF)concentrations are altered in several kinds of coronary heart disease patients. Materials and methods. Using a VEGF enzyme-linked immunosor...Objective. To determine whether serum vascular endothelial growth factor(VEGF)concentrations are altered in several kinds of coronary heart disease patients. Materials and methods. Using a VEGF enzyme-linked immunosorbent assay(ELISA), serum VEGF concentrations were determined in antecubital venous blood of 16 patients with stable angina pectoris(SAP), 16 with unstable angina pectoris(UAP) and 16 with acute myocardial infarction(AMI) before and after thrombolytic therapy, and of 16 age- and sex-matched healthy volunteers who used as controls. Results. The concentrations of serum VEGF in patients with SAP(9860±2699pg/ml) and UAP (10361±2489pg/ml) tended to be higher than those in control subjects(8044±2457pg/ml), but the differences did not reach statistical significance (P>005 for each). Before thrombolytic therapy, the concentrations of serum VEGF in patients with AMI (28592±12515pg/ml) were significantly higher than those in patients with SAP, UAP or control subjects (P<001,respectively), and correlated with synchronous serum creatine kinase (CK) and its MB isoenzyme (CK-MB) contents(r=0866,P<0001 and r=0948,P<0001;respectively). Three hours after thrombolysis, the concentrations of VEGF had fallen to 11157±3129pg/ml (P<001 vs. before thrombolytic therapy and P<005 vs.control subjects). Conclusion. The present study shows that serum concentrations of VEGF in patients with AMI are markedly elevated and that increased serum VEGF levels may be one of the most sensitive indexes in diagnosing AMI and judging reperfusion.展开更多
That the diseases in the interior can be treated at the exterior is one of the therapeutic methods of traditional Chinese medicine. Pretty good results has been obtained in treating the patients of angina pectoris wit...That the diseases in the interior can be treated at the exterior is one of the therapeutic methods of traditional Chinese medicine. Pretty good results has been obtained in treating the patients of angina pectoris with medicinal plaster fixed at acupoints. This is reported as follows.展开更多
Objective： To evaluate the effectiveness and safety of lyophilized Salvia salt of lithospermic acid powder for injection （SSLA） in treating coronary heart diseases angina pectoris （CHD-AP） of Xin-blood stasis syn...Objective： To evaluate the effectiveness and safety of lyophilized Salvia salt of lithospermic acid powder for injection （SSLA） in treating coronary heart diseases angina pectoris （CHD-AP） of Xin-blood stasis syndrome type, and to conduct the non-inferiority trial with Danshen injection （丹参注射液, DSI） as positive control. Methods： An non-inferiority clinical layered, segmented, randomized, and blinded trial on three parallel and multiple centered groups was conducted in 480 patients with stable effort angina grade Ⅰ , Ⅱand Ⅲ, who had two or more times of attack every week. The 240 patients in test group A were treated with SSLA 200 mg added in 250 ml of 5% glucose solution for intravenous dripping every day; the 120 patients in test group B were treated with SSLA but the dosage doubled; and the 120 patients in the control group were treated with DSI 20 ml daily in the same method as SSLA was given. The clinical effectiveness and safety were evaluated after the patients were treated for 14 days. Results： The results showed that the markedly effective rate in test groups A, B and control group was 37.45 %, 36.75 % and 30.09 % respectively, while the total effective rate in them was 88.09%, 89.74% and 67.26% respectively. Statistical significance was shown in comparisons of the therapeutic effect between control group with test group A and test group B, with that in the two test groups superior to that in the control group, and non-inferiority trial showed eligibility （P〈0.01）. Adverse reaction appeared in 8 patients in the test groups and 2 in the control group. Conclusion： SSLA has definite therapeutic effect in treating patients with CHD-AP, with its effect not inferior to that of DSI, and no evident toxic-adverse reaction.展开更多
To summarize and analyze the acupoint selection rules in acupuncture-moxibustion for stable angina pectoris. Clinical studies and literature on acupuncture-moxibustion for stable angina pectoris with definite acupoint...To summarize and analyze the acupoint selection rules in acupuncture-moxibustion for stable angina pectoris. Clinical studies and literature on acupuncture-moxibustion for stable angina pectoris with definite acupoint selection were included through retrieving China National Knowledge Infrastructure（CNKI）,Wanfang Database and VIP in order to analyze the characteristics and rules of acupoint selection in acupuncture-moxibustion treatment for stable angina pectoris. It has been found that the acupoint selection of acupuncture-moxibustion prescriptions for stable angina pectoris focused on specific acupoints.The top 5 acupoints with the highest using frequency included Neiguan（内关PC 6）,Danzhdng（膻中CV17）,Xinshu（心俞BL 15）,Ziusanli（足三里ST 36） and Sanyinjiao（三阴交SP 6）. Acupuncture-moxibustion treatment of stable angina pectoris involved 12 meridians, mainly including the hand-jueyin pericardium meridian, the foot-taiyang bladder meridian, conception vessel, the foot-yangming stomach meridian, the foot-taiyin spleen meridian, and the hand-shaoyin heart meridian, etc., embodying the characteristics and rules of acupoint selection such as ＂highlighting the special treatment effect of acupoints＂ ＂selecting acupoints along the pericardium meridian, bladder meridian and conception vessel, combining the anterior and the posterior acupoints＂, ＂selecting the distal acupoints of spleen and stomach meridians, and focusing on specific acupoints＂, etc.展开更多
Objective:This study aimed to develop a core outcome set(COS)for use in future studies of stable angina pectoris(SAP)in traditional Chinese medicine(TCM).Methods:Systematic literature reviews and qualitative interview...Objective:This study aimed to develop a core outcome set(COS)for use in future studies of stable angina pectoris(SAP)in traditional Chinese medicine(TCM).Methods:Systematic literature reviews and qualitative interviews with cardiologists and patients with SAP treated using TCM were conducted to generate a set of outcomes.Outcomes were prioritized by stakeholders via two rounds of an online Delphi survey and face-to-face consensus meetings.Following the final consensus meeting,a final COS was generated.Results:An initial set of 324 outcomes was identified.A preliminary list of 65 outcomes was employed in the Delphi study.In total,223 participants from seven stakeholder groups were invited to score outcomes in the first Delphi round:87 completed round 1 and 47 completed round 2.Thirty-one participants attended the consensus meeting and agreed on a final core set of outcomes comprising six items across four domains:frequency of angina attack,duration of angina attack,Seattle angina questionnaire,total exercise duration in the exercise treadmill test,cardiovascular events,and QT interval on electrocardiography.Conclusions:The COS developed in this study provides the minimum requirements for measurement and reporting in future TCM clinical trials for the treatment of SAP.The employment of this COS may reduce heterogeneity across trials and facilitate evidencebased decision-making for stakeholders.展开更多
BACKGROUND Coronary artery disease(CAD)is a leading cause of global cardiovascular morta-lity.Refractory angina pectoris,a manifestation of CAD,requires effective drug treatments.Pericarpium Trichosanthis injection,a ...BACKGROUND Coronary artery disease(CAD)is a leading cause of global cardiovascular morta-lity.Refractory angina pectoris,a manifestation of CAD,requires effective drug treatments.Pericarpium Trichosanthis injection,a traditional Chinese medicine,improves cardiovascular symptoms,while nicorandil alleviates spasms and angina.Both have potential in treating CAD.AIM To investigate the therapeutic effects of combining Pericarpium Trichosanthis injection and nicorandil in elderly patients suffering from refractory angina caused by coronary heart disease.METHODS A retrospective analysis was conducted on the data of 130 patients diagnosed with refractory coronary heart disease.Based on the different treatment regimens administered during hospitalization,the patients were divided into a control group(58 cases)and a study group(72 cases).The control group received conven-tional treatment,which included aspirin,statins,and nitrate vasodilators.In addition to the conventional medication,the study group received a combination treatment of Pericarpium Trichosanthis injection and nicorandil.RESULTS After treatment,the study group showed significantly higher left ventricular ejection fraction and cardiac output,and lower brain natriuretic peptide and C-reactive protein levels compared to the control group.The study group also exhibited improvements in angina,quality of life,exercise endurance,and lipid profiles.Multivariate logistic regression analysis revealed a relationship of lipid levels and heart function with the combined treatment.Some patients in the study group experienced headaches during treatment,but no significant adverse reactions were observed.Follow-up showed that the treatment was well-tolerated,with no drug-related adverse reactions detected.CONCLUSION Combination of Pericarpium Trichosanthis injection and nicorandil is more effective than conventional treatment in improving symptoms and heart function in elderly patients with refractory angina pectoris.展开更多
Objective To explore the pharmacodynamic material basis and mechanism of action of volatile oil from Chuanxiong(Chuanxiong Rhizoma)-Suhexiang(Styrax)-Bingpian(Borneolum)(hereinafter referred to as C-S-B volatile oil)i...Objective To explore the pharmacodynamic material basis and mechanism of action of volatile oil from Chuanxiong(Chuanxiong Rhizoma)-Suhexiang(Styrax)-Bingpian(Borneolum)(hereinafter referred to as C-S-B volatile oil)in treating angina pectoris based on network pharmacology and to detect its protective effects against rat myocardial damage.Methods Gas chromatography-mass spectrometry(GC-MS)was used to determine the constituents of volatile oils from Chuanxiong(Chuanxiong Rhizoma),Suhexiang(Styrax),and Bingpian(Borneolum),and the targets of the three main constituents were found predicted and screened using the PharmMapper server,and Gene Cards and Coo LGe N databases.The STRING database and Cytoscape software were used to draw the protein-protein interaction(PPI)network,RStudio software was used to analyze Gene Ontology(GO)and Kyoto Encyclopedia of Genome and Genome(KEGG)pathways,and Cytoscape software was used to construct the component-target-pathwaydisease network.The rat model of myocardial injury was established by intraperitoneal injection of a large dose of isoprenaline hydrochloride.After continuous intervention with C-S-B volatile oil for 14 d,the ejection fraction(EF)and short axis shortening rate(FS)of the left ventricle were detected.The indices of myocardial damage were detected after hematoxylin-eosin(HE)staining.Results Fifteen volatile oil components from the C-S-B formula were identified.There are 470 targets of these volatile oil components and 401 angina-related genes.There are 28 core targets,including CHRM4,ADRA1 A,FGFR1,CHRM2,CYP2 A6,CHRM5,CHRM1,CHRM3,HDAC2,and MPO,etc..The results of the KEGG analysis indicated that the C-S-B formula probably interferes with the following pathways:neuroactive ligand-receptor interactions,calcium signaling,cytochrome P450 metabolism of heteropoietin,among others.The results of animal experiments showed that the C-S-B formula essential oil could significantly improve the following myocardial indices in rats with myocardial injury:EF,FS,left ventricular end-systolic diameter(LVIDs),left ventricular end-diastolic diameter(LVIDd),and stroke volume(SV),and all the differences were statistically significant(P<0.01).Conclusion The mechanism of action of volatile oil components in the C-S-B formula in treating angina pectoris was analyzed using multi-component,multi-target and multi-pathway systems,which has laid a foundation for further revealing its mechanism of action.Animal experiments have shown that the volatile oil of the C-S-B formula can improve EF,FS,and other indices of myocardial damage in a rat model,thus relieving myocardial damage caused by heart hyperactivity,improving cardiac function,and protecting against myocardial damage.展开更多
文摘Minoxidil is a potent vasodilator primarily used for the treatment of severe hypertension,and androgenic alopecia.Although known adverse effects include fluid retention,tachycardia and hypertrichosis,its potential to induce coronary vasospasm remains largely underreported.[1]Minoxidil is currently reserved for treating alopecia for various causes.
文摘Objective:To analyze the efficacy of Tongxinluo Capsules in treating coronary heart disease(CHD)with angina pectoris.Methods:A total of 98 patients with CHD and angina pectoris admitted between May 2022 and May 2025 were enrolled and randomly divided into a control group and an experimental group,with 49 cases each.The control group was treated with atorvastatin+clopidogrel,while the experimental group received atorvastatin+clopidogrel+Tongxinluo Capsules.Clinical efficacy,cardiac function,angina attack frequency and duration,and adverse reactions were compared between the two groups.Results:The experimental group showed higher clinical efficacy than the control group(P<0.05).Cardiac function in the experimental group was superior to that of the control group(P<0.05).The duration and frequency of angina attacks in the experimental group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The use of Tongxinluo Capsules in the clinical treatment of CHD with angina pectoris can improve various clinical indicators,enhance therapeutic efficacy,and promote faster patient recovery.
文摘Objective:To analyze the therapeutic efficacy of Shexiang Baoxin Pill combined with Rosuvastatin Calcium Tablets(ROS)in patients with angina pectoris due to coronary atherosclerotic heart disease(CHD-AP).Methods:Eighty CHD-AP patients admitted for treatment from January 2023 to December 2024 were selected and evenly divided using a random number table.The combined group(40 cases)received treatment with Shexiang Baoxin Pill combined with ROS,while the reference group(40 cases)received ROS monotherapy.The overall response rate,frequency and duration of AP attacks,blood lipid levels,and cardiac function indicators were compared between the two groups.Results:The combined group exhibited a higher overall response rate than the reference group.After treatment,the frequency and duration of AP attacks were lower in the combined group than in the reference group.Additionally,blood lipid levels and cardiac function indicators were superior in the combined group(p<0.05).Conclusion:The combination of Shexiang Baoxin Pill and ROS demonstrates favorable therapeutic effects in CHD-AP patients,effectively preventing AP attacks,regulating blood lipid levels,protecting cardiac function,and reducing disease risk.
基金2023 Special Scientific Research Funding Project for Hospital Pharmacy by the Zhejiang Pharmaceutical Association(Project No.:2023ZYY33)。
文摘Objective:To investigate the clinical efficacy of Shexiang Tongxin Dropping Pills combined with rosuvastatin calcium and clopidogrel bisulfate tablets in treating phlegm-heat and blood stasis type angina pectoris of coronary heart disease.Methods:Sixty-four patients with phlegm-heat and blood stasis type angina pectoris of coronary heart disease,hospitalized at Lin’an District Hospital of Traditional Chinese Medicine from January 2024 to April 2025,were selected and randomly divided into a control group(administered 10mg of rosuvastatin calcium and 75mg of clopidogrel bisulfate once daily)and an observation group(administered 2 Shexiang Tongxin Dropping Pills three times daily in addition to the control group’s treatment regimen),with 32 patients in each group.The therapeutic effects of the two groups were compared.Results:After 56 days of treatment,the angina pectoris score in the observation group was significantly lower than that in the control group(4.49±0.39 vs 4.88±0.47,p<0.05);the Seattle Angina Questionnaire(SAQ)score indicated improvement in the frequency of angina pectoris attacks.(SAQ-AF:71.35±5.29 vs.64.25±7.55,p<0.05)and treatment satisfaction(SAQ-TS:58.79±6.22 vs.54.16±5.02,p<0.05)were more significantly improved in the observation group.The total effective rate(96.87%vs.90.62%,p<0.05)and marked effective rate(62.50%vs.31.25%)were higher in the observation group than in the control group.The Traditional Chinese Medicine(TCM)syndrome score(4.49±0.39 vs.4.88±0.47,p<0.05)and lipid index(LDL-C:1.79±0.31 vs.1.99±0.33 mmol/L,p<0.05)decreased more significantly in the observation group.Conclusion:Shexiang Tongxin Dropping Pills combined with rosuvastatin calcium and clopidogrel bisulfate tablets demonstrated good efficacy and high safety in the treatment of phlegm-heat and blood stasis type angina pectoris associated with coronary heart disease.
基金Supported by the National Scientific Research Project of traditional Chinese Medicine Industry: Research on transformation of Key Technologies for prevention and treatment of Coronary heart Disease with Traditional Chinese Medicine (No. 201007001)the State Administration of Traditional Chinese Medicine: the Research of Shenhong Tongluo Granule based on the theory of Fuxie on acute coronary syndrome by proteomics (JDZX2015046)。
文摘OBJECTIVE: To ascertain whether continuous treatment with Traditional Chinese Medicine(TCM) combined with standardized drug therapy from Western Medicine can further reduce the incidence of cardiovascular events in patients with coronary heart disease and angina and reduce the incidence of angina pectoris in patients with coronary heart disease.METHODS: A multicenter, prospective cohort study of 1042 patients in 22 hospitals was conducted. A total of 423 patients with angina pectoris were treated with standardized Western Medicine alone(control group) and 619 with a combination of Chinese and Western Medicine(exposure group). The two groups underwent follow-up for 1 year to establish whether there was any improvement in the incidence of cardiovascular events or change in the curative effect.RESULTS: The incidence of primary endpoint events in the combined-exposure group decreased by 0.45%(P > 0.05) and the incidence of secondary terminal events decreased by 5.25% in comparison with the control group(P < 0.05). The total angina pectoris score clearly decreased in the Western Medicine group over the first 6 months, but the decline was more apparent in the combined-exposure group.CONCLUSION: Compared with treatment using standardized Western Medicine alone, providing TCM combined with Western medical treatment reduced the incidence of cardiovascular events in patients with stable angina pectoris(grade Ⅱ endpoint) and effectively improved the curative effect.
基金Supported by National Natural Science Foundation of China(Study on the Key Influencing Factors of Anaphylaxis in Traditional Chinese Medicine Injection No.81473547and Multidimensional Clinical Evaluation Model of Salvia Injection for the Treatment of Unstable Angina Pectoris,No.81673829)
文摘OBJECTIVE:To assess the clinical efficacy and safety of ginkgo injections(GIs)combined with conventional treatment(CT)against angina pectoris(AP)due to coronary heart disease(CH D).METHODS:Randomized controlled trials(RCTs)that used GIs to treat AP were searched in SinoMed,PubMed,China National Knowledge Infrastructure Database,Chinese Scientific Journals Database,Wanfang Database,Embase and Cochrane Library until March 2017.The Cochrane "risk of bias" method was used to evaluate the methodological quality of RCTs.Data were analyzed using Stata v13.1 and WinBUGS v1.4.3.RESULTS:A total of 73 RCTs involving 7621 patients were included.A Bayesian network Meta-analysis of RCTs was undertaken,and the advantages of four types of Gl-supplemented CT in AP treatment were determined.CONCLUSION:Gl-assisted CT was more effective against AP than CT alone.However,based on the limitations of the study,additional high-quality RCTs are required to confirm our findings.
基金the Fundamental Research Funds for the Central Public Welfare Research Institutes:Theoretical Study of Combination of Facial Color and Pulses Mode in Traditional Chinese Medicine(No.KJ-202013)Objective Study of“Wei Qi”in Pulse Based on Color Doppler Flow Imaging(CDFI)Technology(No.YZ-202124)。
文摘OBJECTIVE:To evaluate the clinical efficacy of Traditional Chinese Medicine prescriptions for resolving phlegm in the treatment of angina pectoris of phlegmstasis coronary heart disease by a network Meta-analysis.METHODS:Randomized controlled trials(RCTs)on clinical efficacy of CHD angina pectoris with interaction of phlegm and blood stasis were searched in PubMed,Springer,the Cochrane Library and Chinese-language databases China National Knowledge Infrastructure,China Science and Technology Journal Database,and Wanfang Data from their inception to December 2021.Literature was screened and literature bias risk was assessed by RevMan5.4 software.The overall response rate,the duration of angina attack,the levels of serum lipids such as total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C),and high density lipoprotein cholesterol(HDL-C),and expression of hypersensitive C-reactive protein(hs-CRP)were selected as outcome indicators for network Meta-analysis and mapped using Stata15.1 software.RESULTS:Totally,26 RCTs were included,involving 2098 participants.There were 6 TCM formulas with the effects of dispelling phlegm and removing blood stasis.Taking conventional Western Medicine as the common intervention measures,the results showed that the overall response improvement rate from high to low was displayed as modified Xiaoxianxiong decoction(小陷胸汤,MXD),Danlou tablet(丹蒌片,DT),modified Gualou Xiebai Banxia decoction(瓜蒌薤白半夏汤,MGXBD),modified Wendan decoction(温胆汤,MWD),modified Zhishi Xiebai Guizhi decoction(枳实薤白桂枝汤,MZXGD),and modified Erchen decoction(二陈汤,MED).The sequence of angina attack duration improvement from high to low was MZXGD,MGXBD,DT,MWD,MXD.The sequence of TC improvement from high to low was MZXGD,MED,DT,and MGXBD.Sequence of improving TG from high to low was MED,MZXGD,MGXBD,and DT.For LDL-C improvement,the effect from good to poor was MZXGD,MGXBD,DT,and MED.With regard to HDL-C improvement,the effect was ranked as MED,MZXGD,MGXBD,and DT from good to poor.hs-CRP expression from high to low was MZXGD,MXD,MED,MWD,and MGXBD.CONCLUSION:TCM formula with the effects of dispelling phlegm and removing blood stasis combined with conventional Western Medicine has obvious advantages in treating CHD angina pectoris with interaction of phlegm and blood stasis.MZXGD has great potential in increasing the overall response rate,reducing Duration of angina attack improving blood lipids,and reducing inflammatory factors.However,due to the limitations of extant studies,the conclusions of this study need to be confirmed by numerous reasonably-designed RCTs.
文摘OBJECTIVE： To study the preventative effects of Dongchongxiacao （Cordyceps） on contrast-induced nephropathy （CIN） in patients with stable angina pectoris （SAP）. METHODS： One-hundred and three SAP inpatients were divided randomly into two groups： basic treat- ment （n=51） and Dongchongxiacao （Cordyceps） treatment （n=52）; corbrin capsules （3 g; t.d.s.） were used 3 days before angioplasty and 3 days after an- gioplasty）. Serum creatinine （Scr） was assessed at the time of hospital admission and 1, 2, and 3 days after angioplasty. Values of kidney injury mole- cule-1 （KIM-1）, neutrophil gelatinase-associated li- pocalin （NGAL） and interleukin （IL） 18 in the kidney were detected before angioplasty and 1 day after angioplasty in the patients of both groups. The prevalence of CIN between the two groups was then compared. RESULTS： CIN occurred in 9 of 103 patients （8.74%）. The prevalence of CIN in the Dongchongxiacao （Cordyceps） treatment group was lower than that of the basic treatment group （5.77% vs 11.76%） but the difference was not significant （P〉0.05）. The post-procedure mean peak of Scr, post-procedure increase in Scr levels from baseline, and urine levelsof KIM-1, NGAL and IL18 after the procedure in the Dongchongxiacao （Corclyceps） treatment group were significantly lower than those in the basic treatment group （P〈0.05）. CONCLUSION： Prophylactic treatment with Dongchongxiacao （Cordyceps） in SAP patients who undergo coronary angiography or coronary inter- vention could prevent contrast-induced renal im- pairment.
基金Project (No. 2003C33031) supported by the Science and Technology Department of Zhejiang Province, China
文摘Objective： To investigate the relationship between serum resistin level and acute coronary syndrome （ACS） or stable angina pectoris （SAP）. Methods： Sixty-five patients, with coronary artery disease, were enrolled and divided into three subgroups： acute myocardial infarction （AMI）, unstable angina pectoris （UAP） and SAP, and 26 healthy people were recruited as controls in the cross-sectional study. Serum resistin levels were determined by ELISA （enzyme-linked immunosorbent assay）, and WBC （white blood cell count）, hsCRP （high sensitive C-reaction protein）, CKmax （maximum of creatinkinase）, CK-MBmax （maximum of isozyme of creatinkinase） and cTnImax （maximum of troponin） were measured by standard laboratory methods. Results： The serum resistin levels were 4 folds higher in AMI patients, 2.43 folds in UAP patients and I. 12 folds in SAP patients than in the healthy controls （P〈0.05）. The resistin levels were also significantly different between AMI [（8.16±0.79） ng/ml], UAP [（5.59±0.75） ng/ml] and SAP [（3.45±0.56） ng/ml] groups （P〈0.01）; WBC, hsCRP, CK CK-MBmax and cTnlmax were significantly increased in AMI patients over UAP and SAP patients. Spearman analysis showed that serum resistin levels were positively correlated with WBC （r=0.412, P=0.046）, hsCRP （r=0.427,p=0.037）, CK CK-MBmax and cTnImax （r=0.731, 0.678, 0.656; P〈0.01）. Conclusion： Serum resistin levels increased with inflammatory factors and myocardial impairment. The results suggest that human resistin might play an important role in the pathogenesis of atherosclerosis and AMI as an inflammatory factor.
文摘Objective： To evaluate the clinical effect and safety of Safflower Yellow injection （SYI） in treating coronary heart disease angina pectoris （OHD-AP） with Xin-blood stagnation syndrome （XBSS）. Methods： Adopted was the multi-centered, randomized, positive parallel controlled method, 448 patients with CHD-AP-XBSS were enrolled and divided into two groups, 336 in the tested group treated with SYI and 112 in the control group treated with Salvia injection by intravenous dripping once a day for 14 days, so as to observe the conditions of angina, electrocardiogram, and therapeutic effect on traditinal Chinese medicine （TCM） symptoms as well as the safety of the treatment. Results： The significantly effective rate and total effective rate in the tested group were 60.06% （194/323） and 91.02 % （294/323） respectively; those in improvement of TOM symptoms were 40. 18% （129/321） and 75.23% （243/323） respectively, which were better than those in the control group （P〈0.01）. Conclusion： SYI Injection is effective and safe in treating OHD-AP-XBSS.
基金National Science and Technology Major Projects for Major New Drugs Innovation and Development,Key Technology Research on Clinical Efficacy Evaluation of Chinese Herbal Medicines(No.2009ZX09502-029)National Natural Science Foundation of China and the National Key Basic Research Special Foundation of China(No.2013CB531704)
文摘OBJECTIVE: To systematically assess the effects and safety of Sini decoction as an adjuvant therapy for patients with angina pectoris.METHODS: We searched Pub Med, Excerpt Medica Database, the Cochrane library, Wanfang Database,China National Knowledge Infrastructure Database,China Science and Technology Journal Database from the date of its inception until August 1, in2014. Available literatures were selected according to the inclusion criteria. Two reviewers finished data extraction, checked the data and assessed the methodological quality of studies, independently.The Review Manage Software 5.1.0 was used for data analysis.RESULTS: Six trials involving 453 participants were eligible. None of the trials reported the mortality due to angina pectoris. The secondary outcomes showed that Sini decoction, together with nitroglycerin when necessary, may have some effects on reducing the number of angina attacks and the amount of nitroglycerin. But in terms of reducing the duration of angina and improvement of electrocardiogram, there were no statistical differences between Sini decoction group and isosorbide dinitrate group. Only one reported that no adverse events were found.CONCLUSION: Based on this systematic review, Sini decoction can reduce the dosage of nitroglycerin, when compared with isosorbide dinitrate group.And there were no enough evidence in the papers to draw any conclusions for the safety of Sini decoction.
文摘Background The left atrial size has been considered as a useful marker of adverse cardiovascular outcomes. However, it is not well known whether left atrial area index （LAAI） has predictive value for prognosis in patients with unstable angina pectoris （UAP）. This study was aimed to assess the association between LAAI and outcomes in UAP patients. Methods We enrolled a total of 391 in-hospital patients diag- nosed as UAP. Clinical and echocardiographic data at baseline were collected. The patients were followed for the development of ad- verse cardiovascular （CV） events, including hospital readmission for angina pectoris, acute myocardial infarction （AMI）, congestive heart failure （CHF）, stroke and all-cause mortality. Results During a mean follow-up time of 26.3±8.6 months, 98 adverse CV events occurred （84 hospital readmission for angina pectoris, four AMI, four CHF, one stroke and five all-cause mortality）. In a multivariate Cox model, LAAI [OR： 1.140, 95% CI： 1.01±1.279, P = 0.026], diastolic blood pressure （OR： 0.976, 95% CI： 0.956-0.996, P = 0.020） and pulse pressure （OR 1.020, 95% CI： 1.007-1.034, P = 0.004） were independent predictors for adverse CV events in UAP patients. Conclusions LAAI is a predictor of adverse CV events independent of clinical and other echocardiographic parameters in UAP patients.
基金the National Natural Science Foundation of China(the Mechanism of the Effect of Yiqihuoxue Fang on the Vulnerability of Atherosclerotic Plaque by the Way of "DAMPs-PRRs-macrophage",No.81173399)
文摘OBJECTIVE: To use a Meta-analysis to review the efficacy and safety of Gualoupi(Pericarpium Trichosanthis) injection(PTI) in the treatment of angina pectoris.METHODS: We searched the available literature up to January 2015 using Chinese National Knowledge Infrastructure(CNKI), Chinese Scientific Journal Database(VIP), the Wanfang database, Pub Med and other English language databases to identify randomized controlled trials of PTI for the treatment of angina pectoris. Two reviewers independently retrieved and extracted the information. Software Review Manager 5.3 was used for statistics analysis.RESULTS: Fourteen studies involving 1621 patients were identified. Compared with conventional therapy alone or conventional therapy plus other Traditional Chinese Injections(TCMIs), PTI plus conventional therapy significantly improved clinical efficacy [odds ratio(OR) = 3.56, 95% confidence interval(CI)(2.65, 4.77)](based on 14 studies), electrocardiograph efficacy [OR = 3.20, 95% CI(2.26, 4.51)](based on 7 studies), and efficacy for Traditional Chinese Medicine Syndromes [OR = 3.13, 95% CI(1.43, 6.89)](based on 3 studies). Moreover, compared with conventional therapy alone or conventional therapy plus other TCMIs, PTI plus conventional therapy significantly decreased the levels of plasma viscosity [mean difference(MD) =- 0.47,95% CI(-0.76,-0.17)](based on 3 studies), and plasma low-density lipoprotein [MD =-0.94, 95%CI(-1.57,-0.30)](based on 3 studies). Eleven studies reported some mild adverse reactions, and no seriousadversedrugreactionswereobserved.CONCLUSION: PTI was found to be effective and safe for the treatment of angina pectoris. This study had certain limitations; thus, more rigorously designed, multi-center, randomized controlled trials in larger populations should be performed to support this observation.
基金ThisstudywassupportedinpartbythemedicalresearchgrantsofGuangdongProvince (No :A19990 48)
文摘Objective. To determine whether serum vascular endothelial growth factor(VEGF)concentrations are altered in several kinds of coronary heart disease patients. Materials and methods. Using a VEGF enzyme-linked immunosorbent assay(ELISA), serum VEGF concentrations were determined in antecubital venous blood of 16 patients with stable angina pectoris(SAP), 16 with unstable angina pectoris(UAP) and 16 with acute myocardial infarction(AMI) before and after thrombolytic therapy, and of 16 age- and sex-matched healthy volunteers who used as controls. Results. The concentrations of serum VEGF in patients with SAP(9860±2699pg/ml) and UAP (10361±2489pg/ml) tended to be higher than those in control subjects(8044±2457pg/ml), but the differences did not reach statistical significance (P>005 for each). Before thrombolytic therapy, the concentrations of serum VEGF in patients with AMI (28592±12515pg/ml) were significantly higher than those in patients with SAP, UAP or control subjects (P<001,respectively), and correlated with synchronous serum creatine kinase (CK) and its MB isoenzyme (CK-MB) contents(r=0866,P<0001 and r=0948,P<0001;respectively). Three hours after thrombolysis, the concentrations of VEGF had fallen to 11157±3129pg/ml (P<001 vs. before thrombolytic therapy and P<005 vs.control subjects). Conclusion. The present study shows that serum concentrations of VEGF in patients with AMI are markedly elevated and that increased serum VEGF levels may be one of the most sensitive indexes in diagnosing AMI and judging reperfusion.
文摘That the diseases in the interior can be treated at the exterior is one of the therapeutic methods of traditional Chinese medicine. Pretty good results has been obtained in treating the patients of angina pectoris with medicinal plaster fixed at acupoints. This is reported as follows.
基金Supported by the Fund of National Project of High.technicResearch and Development,(No.2003AA223269)
文摘Objective： To evaluate the effectiveness and safety of lyophilized Salvia salt of lithospermic acid powder for injection （SSLA） in treating coronary heart diseases angina pectoris （CHD-AP） of Xin-blood stasis syndrome type, and to conduct the non-inferiority trial with Danshen injection （丹参注射液, DSI） as positive control. Methods： An non-inferiority clinical layered, segmented, randomized, and blinded trial on three parallel and multiple centered groups was conducted in 480 patients with stable effort angina grade Ⅰ , Ⅱand Ⅲ, who had two or more times of attack every week. The 240 patients in test group A were treated with SSLA 200 mg added in 250 ml of 5% glucose solution for intravenous dripping every day; the 120 patients in test group B were treated with SSLA but the dosage doubled; and the 120 patients in the control group were treated with DSI 20 ml daily in the same method as SSLA was given. The clinical effectiveness and safety were evaluated after the patients were treated for 14 days. Results： The results showed that the markedly effective rate in test groups A, B and control group was 37.45 %, 36.75 % and 30.09 % respectively, while the total effective rate in them was 88.09%, 89.74% and 67.26% respectively. Statistical significance was shown in comparisons of the therapeutic effect between control group with test group A and test group B, with that in the two test groups superior to that in the control group, and non-inferiority trial showed eligibility （P〈0.01）. Adverse reaction appeared in 8 patients in the test groups and 2 in the control group. Conclusion： SSLA has definite therapeutic effect in treating patients with CHD-AP, with its effect not inferior to that of DSI, and no evident toxic-adverse reaction.
基金Supported by the special fund of basic scientific research operating expenses of central public welfare scientific research institutions:YZ-1612Natural Science Foundation of Hubei Province:2016CFB215Youth Fund of National Natural Science Foundation of China:81704142~~
文摘To summarize and analyze the acupoint selection rules in acupuncture-moxibustion for stable angina pectoris. Clinical studies and literature on acupuncture-moxibustion for stable angina pectoris with definite acupoint selection were included through retrieving China National Knowledge Infrastructure（CNKI）,Wanfang Database and VIP in order to analyze the characteristics and rules of acupoint selection in acupuncture-moxibustion treatment for stable angina pectoris. It has been found that the acupoint selection of acupuncture-moxibustion prescriptions for stable angina pectoris focused on specific acupoints.The top 5 acupoints with the highest using frequency included Neiguan（内关PC 6）,Danzhdng（膻中CV17）,Xinshu（心俞BL 15）,Ziusanli（足三里ST 36） and Sanyinjiao（三阴交SP 6）. Acupuncture-moxibustion treatment of stable angina pectoris involved 12 meridians, mainly including the hand-jueyin pericardium meridian, the foot-taiyang bladder meridian, conception vessel, the foot-yangming stomach meridian, the foot-taiyin spleen meridian, and the hand-shaoyin heart meridian, etc., embodying the characteristics and rules of acupoint selection such as ＂highlighting the special treatment effect of acupoints＂ ＂selecting acupoints along the pericardium meridian, bladder meridian and conception vessel, combining the anterior and the posterior acupoints＂, ＂selecting the distal acupoints of spleen and stomach meridians, and focusing on specific acupoints＂, etc.
基金supported by the National Natural Science Foundation of China(No.81473544).
文摘Objective:This study aimed to develop a core outcome set(COS)for use in future studies of stable angina pectoris(SAP)in traditional Chinese medicine(TCM).Methods:Systematic literature reviews and qualitative interviews with cardiologists and patients with SAP treated using TCM were conducted to generate a set of outcomes.Outcomes were prioritized by stakeholders via two rounds of an online Delphi survey and face-to-face consensus meetings.Following the final consensus meeting,a final COS was generated.Results:An initial set of 324 outcomes was identified.A preliminary list of 65 outcomes was employed in the Delphi study.In total,223 participants from seven stakeholder groups were invited to score outcomes in the first Delphi round:87 completed round 1 and 47 completed round 2.Thirty-one participants attended the consensus meeting and agreed on a final core set of outcomes comprising six items across four domains:frequency of angina attack,duration of angina attack,Seattle angina questionnaire,total exercise duration in the exercise treadmill test,cardiovascular events,and QT interval on electrocardiography.Conclusions:The COS developed in this study provides the minimum requirements for measurement and reporting in future TCM clinical trials for the treatment of SAP.The employment of this COS may reduce heterogeneity across trials and facilitate evidencebased decision-making for stakeholders.
文摘BACKGROUND Coronary artery disease(CAD)is a leading cause of global cardiovascular morta-lity.Refractory angina pectoris,a manifestation of CAD,requires effective drug treatments.Pericarpium Trichosanthis injection,a traditional Chinese medicine,improves cardiovascular symptoms,while nicorandil alleviates spasms and angina.Both have potential in treating CAD.AIM To investigate the therapeutic effects of combining Pericarpium Trichosanthis injection and nicorandil in elderly patients suffering from refractory angina caused by coronary heart disease.METHODS A retrospective analysis was conducted on the data of 130 patients diagnosed with refractory coronary heart disease.Based on the different treatment regimens administered during hospitalization,the patients were divided into a control group(58 cases)and a study group(72 cases).The control group received conven-tional treatment,which included aspirin,statins,and nitrate vasodilators.In addition to the conventional medication,the study group received a combination treatment of Pericarpium Trichosanthis injection and nicorandil.RESULTS After treatment,the study group showed significantly higher left ventricular ejection fraction and cardiac output,and lower brain natriuretic peptide and C-reactive protein levels compared to the control group.The study group also exhibited improvements in angina,quality of life,exercise endurance,and lipid profiles.Multivariate logistic regression analysis revealed a relationship of lipid levels and heart function with the combined treatment.Some patients in the study group experienced headaches during treatment,but no significant adverse reactions were observed.Follow-up showed that the treatment was well-tolerated,with no drug-related adverse reactions detected.CONCLUSION Combination of Pericarpium Trichosanthis injection and nicorandil is more effective than conventional treatment in improving symptoms and heart function in elderly patients with refractory angina pectoris.
基金funding support from the Major Science and Technology Research and Development Special Project of Jiangxi Science and Technology Department(No.20194ABC28009)National Key Research and Development Plan(No.2018YFC1706404)。
文摘Objective To explore the pharmacodynamic material basis and mechanism of action of volatile oil from Chuanxiong(Chuanxiong Rhizoma)-Suhexiang(Styrax)-Bingpian(Borneolum)(hereinafter referred to as C-S-B volatile oil)in treating angina pectoris based on network pharmacology and to detect its protective effects against rat myocardial damage.Methods Gas chromatography-mass spectrometry(GC-MS)was used to determine the constituents of volatile oils from Chuanxiong(Chuanxiong Rhizoma),Suhexiang(Styrax),and Bingpian(Borneolum),and the targets of the three main constituents were found predicted and screened using the PharmMapper server,and Gene Cards and Coo LGe N databases.The STRING database and Cytoscape software were used to draw the protein-protein interaction(PPI)network,RStudio software was used to analyze Gene Ontology(GO)and Kyoto Encyclopedia of Genome and Genome(KEGG)pathways,and Cytoscape software was used to construct the component-target-pathwaydisease network.The rat model of myocardial injury was established by intraperitoneal injection of a large dose of isoprenaline hydrochloride.After continuous intervention with C-S-B volatile oil for 14 d,the ejection fraction(EF)and short axis shortening rate(FS)of the left ventricle were detected.The indices of myocardial damage were detected after hematoxylin-eosin(HE)staining.Results Fifteen volatile oil components from the C-S-B formula were identified.There are 470 targets of these volatile oil components and 401 angina-related genes.There are 28 core targets,including CHRM4,ADRA1 A,FGFR1,CHRM2,CYP2 A6,CHRM5,CHRM1,CHRM3,HDAC2,and MPO,etc..The results of the KEGG analysis indicated that the C-S-B formula probably interferes with the following pathways:neuroactive ligand-receptor interactions,calcium signaling,cytochrome P450 metabolism of heteropoietin,among others.The results of animal experiments showed that the C-S-B formula essential oil could significantly improve the following myocardial indices in rats with myocardial injury:EF,FS,left ventricular end-systolic diameter(LVIDs),left ventricular end-diastolic diameter(LVIDd),and stroke volume(SV),and all the differences were statistically significant(P<0.01).Conclusion The mechanism of action of volatile oil components in the C-S-B formula in treating angina pectoris was analyzed using multi-component,multi-target and multi-pathway systems,which has laid a foundation for further revealing its mechanism of action.Animal experiments have shown that the volatile oil of the C-S-B formula can improve EF,FS,and other indices of myocardial damage in a rat model,thus relieving myocardial damage caused by heart hyperactivity,improving cardiac function,and protecting against myocardial damage.
